Federal Register / Vol. 89, No. 10 / Tuesday, January 16, 2024 / Notices 2627 

Federal partners, academic institutions, 

the private sector, health professionals, 

professional societies, advocacy groups, 

patient communities, and other 

interested members of the public. 

DATES: The NIH-wide Strategic Plan for 

Autoimmune Disease Research Request 

for Information is open for public 

comment through March 1, 2024. 

Comments must be received by March 1, 

2024, to ensure consideration. 

Comments received after the public 

comment period has closed may be 

considered by the Office of 

Autoimmune Disease Research within 

the Office of Research on Women’s 

Health. 

ADDRESSES: Submissions must be 

submitted electronically via the 

following website: https://rfi.grants.nih.

gov/?s=656f78c997c67a6239036b22. 

FOR FURTHER INFORMATION CONTACT: 

Questions about this request for 

information should be directed to Vicki 

Shanmugam, MBBS, MRCP, FACR, 

CCD, Director, Office of Autoimmune 

Disease Research, Office of Research on 

Women’s Health, 6707 Democracy 

Boulevard, Bethesda, MD 20892, oadrorwh#rfi@od.nih.gov, 301–402–1770. 

SUPPLEMENTARY INFORMATION: This 

notice is in accordance with the 21st 

Century Cures Act, wherein NIH and its 

institutes are required to regularly 

update their strategic plans. In 2022, the 

National Academies of Sciences, 

Engineering, and Medicine report, 

Enhancing NIH Research on 

Autoimmune Diseasehttps://pubmed.

ncbi.nlm.nih.gov/35593778/%22%20/ 

l%20%22:∼:text=Enhancing%20NIH

%20Research%20on%20Autoimmune

%20Disease%20also%20calls,years%29

%20to%20study%20disease%20across

%20the%20life%20course, examined 

NIH research efforts related to 

autoimmune diseases. Subsequently, 

Congress, via the Joint Explanatory 

Statement https://www.appropriations.

senate.gov/imo/media/doc/Division

%20H%20-%20LHHS%20Statement

%20FY23.pdf accompanying the Fiscal 

Year 2023 Consolidated Appropriations 

Act, 2023 directed the establishment of 

an Office of Autoimmune Disease 

Researchhttps://orwh.od.nih.gov/oadrorwh within the Office of Research on 

Women’s Health (OADR–ORWH) 

https://orwh.od.nih.gov/ and directed 

OADR–ORWH to: 

• Coordinate development of a multiinstitute and center (IC) strategic 

research plan; 

• Identify emerging areas of 

innovation and research opportunity; 

• Coordinate and foster collaborative 

research across ICs; 

• Annually evaluate the NIH 

autoimmune disease research portfolio; 

• Provide resources to support 

planning, collaboration, and innovation; 

and 

• Develop a publicly accessible 

central repository for autoimmune 

disease research. 

Currently, various NIH institutes, 

centers, and offices (ICOs) support 

autoimmune disease research in 

alignment with their individual mission 

areas. Establishing an NIH-wide 

Strategic Plan for Autoimmune Disease 

Research will allow OADR–ORWH to 

amplify ICO efforts and create 

opportunities for synergistic innovation 

focused on areas of autoimmune disease 

research that will benefit from multiICO partnerships and opportunities to 

implement cross-cutting research. 

Information Requested 

NIH is seeking input from internal 

and external partners throughout the 

scientific research, advocacy, and 

clinical practice communities, including 

those employed by NIH and by 

institutions receiving NIH support, as 

well as the public, on the following key 

areas related to autoimmune disease 

research: 

Objective 1: Research areas that would 

benefit from cross-cutting, collaborative 

research (these areas may include basic 

or translational research, clinical 

research, health services research, 

population science, data science, 

preventative research, biomedical 

engineering, and other areas of 

research). 

Objective 2: Opportunities to advance 

collaborative, innovative, or 

interdisciplinary areas of autoimmune 

disease research. 

Objective 3: Opportunities to improve 

outcomes for individuals living with 

autoimmune diseases including NIHdesignated health disparities 

populations https://

www.nimhd.nih.gov/about/overview/, 

populations and individuals with rare 

diseases, and specific populations that 

have been historically underrepresented 

in research and clinical trials. 

Objective 4: Cross-cutting areas that 

are integral to advancing autoimmune 

disease research at NIH including 

development of a publicly accessible 

central repository for autoimmune 

disease research, sex- and genderintentional research design across all 

stages of research, and engagement of all 

populations in research and clinical 

trials. 

Responses to this RFI are voluntary 

and are meant for information and 

planning purposes only. Do not include 

any proprietary, classified, confidential, 

trade secret, or sensitive information in 

your response. Respondents are advised 

that the responses are reviewed by NIH 

staff, and the U.S. government is under 

no obligation to acknowledge receipt of 

the information provided or provide 

feedback to the respondents. This RFI is 

for planning purposes only and should 

not be construed as a solicitation, grant, 

or cooperative agreement, or as an 

obligation on the part of the federal 

government, the NIH, or individual NIH 

institutes, centers, and offices to provide 

any kind of support for any ideas 

identified in response to it. 

The government may use the 

information submitted in response to 

this RFI at its discretion. The 

government reserves the right to use any 

submitted information on public NIH 

websites, in reports, in summaries of the 

state of the science, in any possible 

resultant solicitation(s), grant(s), or 

cooperative agreement(s), or in the 

development of future funding 

announcements. 

The government will not pay for the 

preparation of any information 

submitted or for the government’s use of 

such information. No basis for claims 

against the U.S. government shall arise 

as a result of a response to this request 

for information or from the 

government’s use of such information. 

NIH looks forward to your input, and 

we hope that you will share this RFI 

document with your colleagues. 

Dated: January 6, 2024. 

Lawrence A. Tabak, 

Principal Deputy Director, National Institutes 

of Health. 

[FR Doc. 2024–00695 Filed 1–12–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Drug Abuse; 

Amended Notice of Meeting 

Notice is hereby given of a change in 

the meeting of the National Institute on 

Drug Abuse Special Emphasis Panel, 

February 13, 2024, 10:00 a.m. to 

February 14, 2024, 05:00 p.m., National 

Institute of Health, National Institute on 

Drug Abuse, 301 North Stonestreet 

Avenue, Bethesda, MD 20892 which 

was published in the Federal Register 

on November 24, 2023, FR Doc 2023– 

25938, 88 FR 82387. 

This notice is being amended to 

change the meeting date from February 

13–14, 2024 to February 14, 2024. The 

meeting time and location will remain 


ddrumheller on DSK120RN23PROD with NOTICES1
2628 Federal Register / Vol. 89, No. 10 / Tuesday, January 16, 2024 / Notices 

the same. The meeting is closed to the 

public. 

Dated: January 10, 2024. 

Lauren A. Fleck, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–00667 Filed 1–12–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Aging; Notice of 

Closed Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Aging Special Emphasis Panel; Healthcare 

Decision Making. 

Date: January 30, 2024. 

Time: 1:00 p.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute on Aging, 

Gateway Building, 7201 Wisconsin Avenue, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Kimberly Firth, Ph.D., 

National Institutes of Health, National 

Institute on Aging, Gateway Building, 7201 

Wisconsin Avenue, Suite 2C212, Bethesda, 

MD 20892, 301–402–7702, firthkm@

mail.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.866, Aging Research, 

National Institutes of Health, HHS) 

Dated: January 10, 2024. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–00671 Filed 1–12–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of General Medical 

Sciences; Notice of Closed Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

General Medical Sciences Initial Review 

Group; Training and Workforce Development 

Study Section—C Training and Workforce 

Development Study Section C (TWD–C)— 

Review of B2B, B2D and IRACDA. 

Date: February 22, 2024. 

Time: 10:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

National Institute of General Medical 

Sciences, Natcher Building, 45 Center Drive, 

Bethesda, Maryland 20892 (Virtual Meeting). 

Contact Person: Sonia Ivette OrtizMiranda, Ph.D., Scientific Review Officer, 

Scientific Review Branch, National Institute 

of General Medical Sciences, National 

Institutes of Health, 45 Center Drive, MSC 

6200 Bethesda, Maryland 20892, 301–402– 

9448, sonia.ortiz-miranda@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program No. 93.859, Biomedical Research 

and Research Training, National Institutes of 

Health, HHS) 

Dated: January 9, 2024. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–00635 Filed 1–12–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Aging; Notice of 

Closed Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Aging Special Emphasis Panel; Brain Aging 

Models. 

Date: February 21, 2024. 

Time: 10:00 a.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute on Aging, 

Gateway Building, 7201 Wisconsin Avenue, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Bita Nakhai, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, National Institute on Aging, 7201 

Wisconsin Avenue Gateway Bldg., Suite 

2C212, Bethesda, MD 20892, 301–402–7701, 

nakhaib@nia.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.866, Aging Research, 

National Institutes of Health, HHS) 

Dated: January 10, 2024. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–00670 Filed 1–12–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Center for Complementary & 

Integrative Health; Notice of Closed 

Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Center for 

Complementary and Integrative Health 

Special Emphasis Panel; NCCIH Training and 

Education Review Panel (CT). 

Date: March 7–8, 2024. 

Time: 10:00 a.m. to 4:00 p.m. 


ddrumheller on DSK120RN23PROD with NOTICES1